Table 1.
Characteristics of the Study Cohort, Stratified by COVID-19 Infection Status
| Characteristic | COVID-positive (n = 39) | COVID-negative (n = 5263) | P |
|---|---|---|---|
| Mean age (in years) (SD) | 45.6 (18.8) | 46.6 (18.3) | 0.74 |
| Sex | 0.18 | ||
| Male | 38% | 49% | |
| Female | 62% | 51% | |
| Race | 0.81 | ||
| White | 90% | 89% | |
| Nonwhite / missing | 10% | 11% | |
| IBD-type | 0.063 | ||
| Crohn’s disease | 44% | 58% | |
| Ulcerative colitis | 56% | 42% | |
| Comorbidities | |||
| Obesity | 28% | 6% | < 0.001 |
| Diabetes mellitus | 8% | 7% | 0.71 |
| Hypertension | 18% | 21% | 0.70 |
| Asthma | 10% | 6% | 0.31 |
| Medication category | 0.38 | ||
| 5-aminosalicylates | 31% | 35% | |
| Immunomodulator | 8% | 11% | |
| TNF-antagonists | 33% | 25% | |
| Vedolizumab | 18% | 11% | |
| Ustekinumab | 0% | 7% | |
| Tofacitinib | 0% | 1% | |
| Combination therapya | 10% | 10% | |
| Prednisone use | 0.95 | ||
| No | 79% | 80% | |
| Yes | 21% | 20% |
aCombination therapy refers to use of TNF-antagonists, vedolizumab, or ustekinumab in combination with an immunomodulator (azathioprine, mercaptopurine, methotrexate).